Skip to content

A single-center, randomized, double-blind, placebo, parallel-controlled clinical study of Jinfei Zhisu Powder in the treatment of cough after cold pathogenic pulmonary infection

Study on the curative effect of Jinfei Zhisu Powder in treating cough after infection of cold pathogen and lung-loving type

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400086585
Enrollment
Unknown
Registered
2024-07-05
Start date
2024-07-10
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

post-infectious cough

Interventions

Treatment group:Jinfei Zhisu SAN granules, 1 dose a day, divided into 2 times. Compound methoxyamine capsule, 2 capsules 3 times a day, continuous administration. The course of treatment was 14 days a
Control group:Jinfei Zhisusan granule simulator (containing 5% of the active ingredient of the original formula), 1 dose a day, divided into 2 times. Compound methoxyamine capsule, 2 capsules 3 times

Sponsors

Xiyuan Hospital, China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Post-infectious cough diagnosed by Western medicine; (2) TCM syndrome differentiation is syndrome of cold evil loving lung; (3) Age 18-70 years old; (4) Not participating in other clinical researchers in the past 1 month; (5) Those who voluntarily accept clinical trials and sign informed consent.

Exclusion criteria

Exclusion criteria: (1) Pulmonary function screening was performed before enrollment to exclude chronic cough caused by other factors, such as cough variant asthma, chronic bronchitis, bronchiectasis, chronic obstructive pulmonary disease, postnasal trickling syndrome, gastroesophageal reflux cough, eosinophilic bronchitis, allergic cough, and angiotensin-converting enzyme inhibitors; (2) Blood routine and chest CT screening before enrollment were performed to exclude patients with acute respiratory tract infection; (3) Allergic constitution or allergic to the experimental drug; (4) Patients with heart disease, hypertension, hyperthyroidism, chronic obstructive pulmonary disease, liver disease, glaucoma, dysuria and the elderly; (5) Patients with severe cardiovascular and cerebrovascular diseases, abnormal liver function or abnormal kidney function; (6) Patients with malignant tumor, blood system disease and mental illness; (7) Women who are preparing for pregnancy, during pregnancy or breastfeeding; (8) Other conditions deemed unsuitable by the researcher.

Design outcomes

Primary

MeasureTime frame
Visual analogue scale;

Secondary

MeasureTime frame
Cough evaluation test;Leicester cough questionnaire;Time of onset of treatment;Cough symptoms disappear time;TCM syndrome score;

Countries

China

Contacts

Public ContactYuan Shasha

Xiyuan Hospital, China Academy of Chinese Medical Sciences

384482587@qq.com+86 183 0110 3200

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026